Stocksigma LogoStocksigma Logo

Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions

Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 mn for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 mn and 11.8%

Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions

Marksans Pharma Ltd · Outcome · 04 Nov 2026, 7:04 pm

Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 mn for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 mn and 11.8% QoQ. Consolidated net profit attributable to owners reached ₹1,413.12 mn versus ₹982.50 mn in Q2 FY26 (up 43.8% YoY). For H1 FY27, revenue rose 32.8% YoY to ₹17,809.65 mn with PAT of ₹2,984.79 mn. The company completed 100% acquisitions of Dutch distributor QliniQ B.V. for EUR 7.50 mn and German-based ABCnow GmbH for EUR 1.10 mn.

Original exchange filing (PDF)

More announcements from Marksans Pharma Ltd

All Marksans Pharma Ltd announcements